News for '-v-2'

Cold, Flu Or COVID-19? Know The Difference

Cold, Flu Or COVID-19? Know The Difference

Rediff.com24 Jan 2022

Dr Karthiyayini Mahadevan tells you how to differentiate between a cold, flu and COVID-19 and take appropriate action.

Problems related to bones, muscles persist post Covid

Problems related to bones, muscles persist post Covid

Rediff.com12 Oct 2021

The systemic inflammatory response to SARS-CoV-2 adversely impacts the musculoskeletal system. Inflammatory molecules break the muscle fiber protein and decrease muscle protein synthesis leading to decreased muscle strength and also weaken bones.

Covishield booster works against Omicron

Covishield booster works against Omicron

Rediff.com24 Dec 2021

If the vaccine is recommended for use as a booster against Omicron, it may significantly boost the demand for Covishield in India.

Scientists find different variant of Covid virus in South India

Scientists find different variant of Covid virus in South India

Rediff.com28 Jan 2021

Scientists at the CSIR-Centre for Cellular and Molecular Biology in Hyderabad have found prominently a different variant of SARS-CoV-2 in southern parts of India, a top official of the institute said on Thursday.

Every Covid patient infecting 2 others as Delhi's R-value up to 2.1: IIT

Every Covid patient infecting 2 others as Delhi's R-value up to 2.1: IIT

Rediff.com23 Apr 2022

Delhi's R-value, which indicates the spread of COVID-19, was recorded at 2.1 this week, implying that every infected person is infecting two others in the national capital, according to an analysis by IIT-Madras.

WHO clears Serum Institute's Covovax for emergency use

WHO clears Serum Institute's Covovax for emergency use

Rediff.com18 Dec 2021

'WHO issued an emergency use listing for Covovax, expanding the basket of WHO-validated vaccines against COVID-19. The vaccine is produced by the Serum Institute of India under licence from Novavax,' the world health body said in a tweet on Friday.

Covaxin's 50 pc efficacy adequate for Covid, say experts

Covaxin's 50 pc efficacy adequate for Covid, say experts

Rediff.com26 Nov 2021

The decline in the effectiveness of Covaxin, India's indigenous COVID-19 vaccine, from 77.8 per cent to 50 per cent during a Delta-driven case surge in April and May this year is neither bad nor surprising, say scientists.

Covaxin: No serious adverse events in phase 1 trials

Covaxin: No serious adverse events in phase 1 trials

Rediff.com16 Dec 2020

The vaccine induced robust binding and neutralising antibody responses which were comparable to those observed in the convalescent serum collected from patients who had recovered from COVID-19, according to the findings which have appeared on medRxiv, a preprint server.

Scientists identify 70 drugs that may fight COVID-19

Scientists identify 70 drugs that may fight COVID-19

Rediff.com26 Mar 2020

The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains, according to the researchers.

Lancet Study finds Russian vaccine safe, effective

Lancet Study finds Russian vaccine safe, effective

Rediff.com4 Sep 2020

Results from early-phase non-randomised vaccine trials in a total of 76 people show that two formulations of the vaccine have a good safety profile detected over 42 days, and induce antibody responses in all participants within 21 days.

Study comparing Covishield, Covaxin has limitations: Bharat Biotech

Study comparing Covishield, Covaxin has limitations: Bharat Biotech

Rediff.com9 Jun 2021

Raches Ella, project lead, Covid-19 vaccines at Bharat Biotech said in a series of tweets that he was 'surprised' that media and researchers were drawing conclusions based on non-peer reviewed work.

New Covid XE variant not more severe than Omicron: Dr Kang of CMC Vellore

New Covid XE variant not more severe than Omicron: Dr Kang of CMC Vellore

Rediff.com8 Apr 2022

The World Health Organisation has issued warning against XE, a new variant of Omicron first detected in the UK.

Children are silent spreaders of coronavirus: Study

Children are silent spreaders of coronavirus: Study

Rediff.com20 Aug 2020

The study, published in the Journal of Pediatrics, also challenges the current hypothesis that because children have lower numbers of immune receptors for SARS-CoV2, the virus that causes COVID-19, this makes them less likely to become infected or seriously ill.

Future Covid waves unlikely to have serious impact in India: Experts

Future Covid waves unlikely to have serious impact in India: Experts

Rediff.com20 Mar 2022

The reason is that because of the hybrid immunity after three waves of natural infection and a large proportion of adults receiving both doses of COVID-19 vaccine, the susceptible pool has come down drastically, Lahariya said.

Omicron survives much longer on plastic, skin: Study

Omicron survives much longer on plastic, skin: Study

Rediff.com26 Jan 2022

The yet-to-be peer-reviewed study, posted recently on the preprint repository BioRxiv, found that the Alpha, Beta, Delta, and Omicron variants exhibited more than two-fold longer survival on plastic and skin surfaces, than the Wuhan strain.

India's Feluda COVID test cheaper alternative to RT-PCR, say scientists

India's Feluda COVID test cheaper alternative to RT-PCR, say scientists

Rediff.com28 Sep 2020

Named after Satyajit Ray's famed detective, the Feluda test, which is priced at Rs 500 and can deliver a result in 45 minutes, is able to differentiate SARS-CoV-2 from other coronaviruses even if genetic variations between them are minute.

Centre issues alert to states over Tomato Flu in children

Centre issues alert to states over Tomato Flu in children

Rediff.com24 Aug 2022

Centre has sent an advisory to states on HFMD (Hand Foot and Mouth Disease), commonly known as Tomato Flu, stating that it's a self-limiting illness targeting mostly young children aged 1-10 years and immune-compromised adults and no specific drug exists to treat it.

8 vaccines, 4 treatments in India's COVID-19 arsenal

8 vaccines, 4 treatments in India's COVID-19 arsenal

Rediff.com28 Dec 2021

The Central Drugs Standard Control Organisation has granted restricted emergency use authorisation to two new vaccines and a drug for COVID-19, taking the number of preventives and treatments available in India to 12.

'No need to give special attention to COVID-19 anymore'

'No need to give special attention to COVID-19 anymore'

Rediff.com22 Aug 2022

'All actions for COVID-19 should be the same as for other routine health conditions.' 'There is no need to report the matter in the media all the time; not on front page please.'

2021: How Covid kept the world on tenterhooks, with surprises aplenty

2021: How Covid kept the world on tenterhooks, with surprises aplenty

Rediff.com29 Dec 2021

As the Omicron strain spreads across the globe and questions on vaccine inequity dominate discussions, scientists are still scrambling to learn more about emerging variants of the deadly virus that has claimed millions of lives and crippled economies.

COVID-19 in India may have orginated from EU, Middle East: Study

COVID-19 in India may have orginated from EU, Middle East: Study

Rediff.com9 Jun 2020

The objective of the study was to determine the genetic diversity among Indian SARS-CoV-2 viral isolates in comparison to the strains that are occurring worldwide.

Indian Covid variant found in 44 countries: WHO

Indian Covid variant found in 44 countries: WHO

Rediff.com12 May 2021

The coronavirus variant B.1.617 first identified in India last year has been classified as a "variant of global concern", with some preliminary studies showing that it spreads more easily, a senior WHO official had said on Monday.

'We can't get rid of COVID-19 for a long time to come'

'We can't get rid of COVID-19 for a long time to come'

Rediff.com10 Jun 2022

'There will be ups and downs, and we have to plan how we live with it now.'

Delta plus: New Covid variant identified in India

Delta plus: New Covid variant identified in India

Rediff.com14 Jun 2021

The highly transmissible Delta variant of SARS-CoV-2 has mutated further to form the 'Delta plus' or 'AY.1' variant but there is no immediate cause for concern in India as its incidence in the country is still low, scientists in New Delhi said.

Delta Plus variant: Govt alerts 8 states, UTs

Delta Plus variant: Govt alerts 8 states, UTs

Rediff.com25 Jun 2021

The Union health ministry on Friday urged eight states and Union Territories to take up immediate containment measures including preventing crowds, conducting widespread testing as well as increasing vaccine coverage on a priority basis in districts where the Delta Plus variant of coronavirus has been detected.

First COVID-19 vaccine human trial finds it's safe

First COVID-19 vaccine human trial finds it's safe

Rediff.com23 May 2020

The first COVID-19 vaccine to reach phase I clinical trial is safe, well-tolerated, and capable of generating an immune response against the novel coronavirus in humans, says a new research published in The Lancet journal.

Omicron in community transmission stage in India: INSACOG

Omicron in community transmission stage in India: INSACOG

Rediff.com23 Jan 2022

The Omicron variant of COVID-19 is in the community transmission stage in India and it has also become dominant in multiple metros, where new cases have been rising exponentially, said Indian SARS-CoV-2 Genomics Consortium.

Ahead of Covid vaccine rollout, Centre issues dos and don'ts

Ahead of Covid vaccine rollout, Centre issues dos and don'ts

Rediff.com14 Jan 2021

In a letter to all states and Union territories, the ministry highlighted that under the emergency use authorisation, coronavirus vaccination is indicated only for 18 years and above. If required, COVID-19 vaccine and other vaccines should be separated by an interval of at least 14 days.

Pune's NIV develops ELISA test to detect COVID-19 antibodies

Pune's NIV develops ELISA test to detect COVID-19 antibodies

Rediff.com10 May 2020

The test kit has the advantage of testing 90 samples together in a single run of 2.5 hours, so that healthcare professionals can proceed quickly with necessary next steps.

With Axar yet to recover, Delhi Capitals induct Mulani

With Axar yet to recover, Delhi Capitals induct Mulani

Rediff.com15 Apr 2021

Delhi Capitals have brought in Shams Mulani as a short-term COVID-19 replacement for Axar Patel for their IPL-2021 campaign.

Scientists believe Covid nearing its end, but also advise caution

Scientists believe Covid nearing its end, but also advise caution

Rediff.com23 Sep 2022

The pandemic will be over but Covid will be here to stay, the scientists said as Covid numbers begin to ebb in several parts of the world, including India.

Watching global Covid spread, IIT-Kanpur has not predicted 4th wave: Govt

Watching global Covid spread, IIT-Kanpur has not predicted 4th wave: Govt

Rediff.com22 Mar 2022

Noting that various mathematical models meant for predicting coronavirus waves have repeatedly failed to give reliable results due to a small sample size, the Centre on Tuesday said it is closely following the virus trajectory globally, given the emergence of its new variants.

Covid: PM chairs high-level meet, stresses on oxygen availability

Covid: PM chairs high-level meet, stresses on oxygen availability

Rediff.com11 Sep 2021

Modi stressed on the need for constant genome sequencing to monitor emergence of mutants and also to ensure increased oxygen availability, the Prime Minister's Office (PMO) said in a statement.

Covid vax don't give total protection: WHO scientist

Covid vax don't give total protection: WHO scientist

Rediff.com12 Aug 2021

"Even though the vaccine may not be able to provide absolute protection against different variants of virus, it can certainly reduce the risk of death and complications," a statement quoting WHO chief scientist Soumya Swaminathan said.

Molnupiravir not to be included in Covid treatment now

Molnupiravir not to be included in Covid treatment now

Rediff.com11 Jan 2022

The Indian Council of Medical Research's national task force for COVID-19 has decided against including antiviral drug Molnupiravir in the clinical management protocol for COVID-19 as of now, official sources said on Tuesday.

Covid 3rd wave unlikely to be as severe as second: Study

Covid 3rd wave unlikely to be as severe as second: Study

Rediff.com25 Jun 2021

A third wave of COVID-19 -- if it occurs -- is unlikely to be as severe as the second wave given the extent of spread of coronavirus infections that has already taken place in the country, according to a study.

Rahul V2.0 tears into BJP, says democarcy not rule by one man

Rahul V2.0 tears into BJP, says democarcy not rule by one man

Rediff.com17 Jan 2014

Seeking to dispel the demoralisation in Congress in the wake of recent electoral debacle, a combative Rahul Gandhi today mounted a blistering attack on Narendra Modi saying those dreaming about Congress-free India will themselves be destroyed.

Recovered people showing faster response to Covishield: Study

Recovered people showing faster response to Covishield: Study

Rediff.com3 Mar 2021

Those who have recovered from COVID-19 respond faster to the Covishield vaccine and reach high antibody levels, says a study, leading to hopes that they may not need a second dose and therefore help widen India's corona immunisation cover.

Gujarat Omicron patient's kin also test positive for the same

Gujarat Omicron patient's kin also test positive for the same

Rediff.com10 Dec 2021

The wife and brother-in-law of an NRI man, who had been found infected with the Omicron variant of COVID-19 here in Gujarat a week back, were also detected with the new strain, officials of the Jamnagar Municipal Corporation (JMC) said on Friday.

2 gorillas at US zoo test positive for COVID-19

2 gorillas at US zoo test positive for COVID-19

Rediff.com17 Jan 2021

According to the zoo, two of the gorillas had started coughing on Wednesday, following which San Diego Zoo Global initiated the process of testing fecal samples from them for SARS-CoV-2 through the California Animal Health and Food Safety Laboratory System.